OncoMatch/Clinical Trials/NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT07258511 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including JNJ-79635322 and Teclistamab for multiple myeloma.
Treatment: JNJ-79635322 · Teclistamab — The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory drug
Must have received: anti-cd38 antibody
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USC Norris Comprehensive Cancer Center · Los Angeles, California
- University of Connecticut Health Center · Farmington, Connecticut
- Yale Cancer Center · New Haven, Connecticut
- Florida Cancer Specialists & Research Institute · Fort Myers, Florida
- Emory University · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07258511 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received proteasome inhibitor and immunomodulatory drug.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages